These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7328487)

  • 1. Further investigations on the binding of loop diuretics to serum proteins from patients with liver disease.
    Goto S; Yoshitomi H; Miyamoto A; Yamada H; Fujii S; Nakayama T; Fujiwara K
    J Pharmacobiodyn; 1981 Nov; 4(11):865-73. PubMed ID: 7328487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of several loop diuretics to serum albumin and human serum from patients with renal failure and liver disease.
    Goto S; Yoshitomi H; Miyamoto A; Inoue K; Nakano M
    J Pharmacobiodyn; 1980 Dec; 3(12):667-76. PubMed ID: 7277182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin binding of bumetanide.
    Robertson A; Karp W
    Dev Pharmacol Ther; 1986; 9(4):241-8. PubMed ID: 3757731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mode of interaction of loop diuretics with human serum albumin and characterization of binding site.
    Takamura N; Haruta A; Kodama H; Tsuruoka M; Yamasaki K; Suenaga A; Otagiri M
    Pharm Res; 1996 Jul; 13(7):1015-9. PubMed ID: 8842038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical comparative trial of piretanide and furosemide in patients with advanced renal insufficiency. Drug levels and diuretic potency of single oral doses].
    Heuer LJ; Machnik H; Studt J; Fink R
    Arzneimittelforschung; 1983; 33(9):1318-21. PubMed ID: 6685516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative evaluation of ototoxic side effects of furosemide, piretanide, bumetanide, azosemide and ozolinone in the cat--a new approach to the problem of ototoxicity.
    Göttl KH; Roesch A; Klinke R
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):275-82. PubMed ID: 4088324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piretanide: a loop-active diuretic. Pharmacology, therapeutic efficacy and adverse effects.
    Marsh JD; Smith TW
    Pharmacotherapy; 1984; 4(4):170-80. PubMed ID: 6384944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein binding of piretanide in normal and uraemic serum.
    Elliott HL; Ansari AF; Campbell BC; Lawrence JR
    Eur J Clin Pharmacol; 1982; 21(4):311-3. PubMed ID: 7056276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal actions of piretanide and three other "loop" diuretics.
    McNabb WR; Noormohamed FH; Brooks BA; Lant AF
    Clin Pharmacol Ther; 1984 Mar; 35(3):328-37. PubMed ID: 6697640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum protein binding of propofol in patients with renal failure or hepatic cirrhosis.
    Costela JL; Jiménez R; Calvo R; Suárez E; Carlos R
    Acta Anaesthesiol Scand; 1996 Jul; 40(6):741-5. PubMed ID: 8836272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial.
    Gentilini P; Casini-Raggi V; Di Fiore G; Romanelli RG; Buzzelli G; Pinzani M; La Villa G; Laffi G
    J Hepatol; 1999 Apr; 30(4):639-45. PubMed ID: 10207805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Decreased serum protein binding of glymidine in icteric liver disease and its partial correction with charcoal (author's transl].
    Held H
    Klin Wochenschr; 1979 Jul; 57(13):693-5. PubMed ID: 158106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanism of action of xipamide and its classification as a "low ceiling diuretic". Pharmacodynamic-pharmacokinetic studies in healthy volunteers and in kidney and liver patients].
    Knauf H; Mutschler E
    Arzneimittelforschung; 2005; 55(1):1-14. PubMed ID: 15727159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilirubin displaces furosemide from serum protein: the effect is greater in newborn infants than adult subjects.
    Viani A; Pacifici GM
    Dev Pharmacol Ther; 1989; 14(2):90-5. PubMed ID: 2630237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics and pharmacodynamics of torasemide.
    Knauf H; Mutschler E
    Clin Pharmacokinet; 1998 Jan; 34(1):1-24. PubMed ID: 9474471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level.
    Arroyo V; Bosch J; Casamitjana R; Cabrera J; Rivera F; Rodés J
    Gut; 1980 Oct; 21(10):855-9. PubMed ID: 7439805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma protein binding of frusemide in liver disease: effect of hypoalbuminaemia and hyperbilirubinaemia.
    Viani A; Carrai M; Pacifici GM
    Br J Clin Pharmacol; 1989 Aug; 28(2):175-8. PubMed ID: 2775623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loop diuretic therapy in liver cirrhosis with ascites.
    Laffi G; La Villa G; Carloni V; Foschi M; Bartoletti L; Quartini M; Gentilini P
    J Cardiovasc Pharmacol; 1993; 22 Suppl 3():S51-8. PubMed ID: 7506337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein binding and bilirubin displacing properties of bumetanide and furosemide.
    Turmen T; Thom P; Louridas AT; LeMorvan P; Aranda JV
    J Clin Pharmacol; 1982; 22(11-12):551-6. PubMed ID: 7161408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rat NKCC2/NKCC1 cotransporter selectivity for loop diuretic drugs.
    Hannaert P; Alvarez-Guerra M; Pirot D; Nazaret C; Garay RP
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Mar; 365(3):193-9. PubMed ID: 11882915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.